MBX Biosciences, Inc. (MBX) Key Metrics
MBX valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $2.39B
- Enterprise value
- $2.37B
- P/E (TTM)
- —
- Forward P/E
- —
- PEG ratio
- —
- Price / sales
- —
- Price / book
- 6.8
- EV / EBITDA
- —
- Dividend yield
- —
- Beta
- 0.10
MBX key metrics, 2022–2025
Fiscal year ended December 31, 2025 · U.S. dollarsMBX valuation Price multiples at each fiscal year-end price.
MBX returns How much profit the business earns on the capital it uses.
MBX per-share figures Results divided by the shares outstanding at year-end.
MBX financial health Debt, liquidity and how easily interest is covered.
MBX efficiency & capital use Working capital cycle and where the cash goes.
MBX valuation history
MBX returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
MBX debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
MBX price vs earnings per share
MBX key metrics
2022–2025| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Valuation | ||||
| Market capitalization | $1.15B | $615.4M | — | — |
| Enterprise value | $778.3M | $353.4M | — | — |
| Price / book | 3.1 | 2.4 | — | — |
| Earnings yield | −7.6% | −10.1% | — | — |
| Free cash flow yield | −7.1% | −9.0% | — | — |
| Share price at fiscal year-end | $31.54 | $18.43 | — | — |
| Per share | ||||
| Revenue per share | $0.00 | $0.00 | $0.00 | $0.00 |
| Earnings per share | −$2.38 | −$1.85 | −$1.02 | −$0.82 |
| Operating cash flow per share | −$2.19 | −$1.64 | −$1.00 | −$0.73 |
| Free cash flow per share | −$2.24 | −$1.66 | −$1.01 | −$0.74 |
| Cash per share | $10.24 | $7.85 | $2.53 | $1.33 |
| Book value per share | $10.11 | $7.71 | −$2.28 | −$1.34 |
| Tangible book value per share | $10.11 | $7.71 | −$2.28 | −$1.34 |
| Capex per share | $0.05 | $0.03 | $0.00 | $0.01 |
| Debt per share | $0.02 | $0.01 | $0.01 | $0.01 |
| Shares outstanding | 36.5M | 33.4M | 31.9M | 31.9M |
| Change in shares outstanding | +9.3% | +4.8% | 0.0% | — |
| Returns & profitability | ||||
| Return on equity (ROE) | −27.8% | −67.0% | — | — |
| Return on assets (ROA) | −26.6% | −35.1% | −50.4% | −58.0% |
| Return on tangible assets | −22.6% | −23.1% | −38.7% | −58.0% |
| Financial health | ||||
| Total debt | $596,000 | $171,000 | $324,000 | $461,000 |
| Cash & short-term investments | $373.7M | $262.1M | $80.7M | $42.5M |
| Net debt | −$373.1M | −$262.0M | −$80.4M | −$42.0M |
| Debt / equity | 0.00 | 0.00 | — | — |
| Debt / assets | 0.00 | 0.00 | 0.00 | 0.01 |
| Current ratio | 24.62 | 24.19 | 21.26 | 12.89 |
| Quick ratio | 24.62 | 24.19 | 21.26 | 12.89 |
| Interest coverage | — | — | — | -67.3 |
| Working capital | $366.0M | $256.2M | $79.5M | $40.8M |
| Invested capital | −$3.9M | −$4.5M | −$152.8M | −$84.6M |
| Tangible asset value | $369.2M | $257.4M | −$72.5M | −$42.6M |
| Net current asset value | $365.6M | $256.2M | −$73.2M | −$43.5M |
| Graham net-net per share | $9.84 | $7.53 | −$2.38 | −$1.42 |
| Capital allocation | ||||
| Capex / depreciation | 7.78 | 3.58 | 0.82 | 7.88 |
| Efficiency | ||||
| Days payables outstanding | 6,116.7 | 5,030.7 | 2,751.4 | 6,361.4 |
| Receivables turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Payables turnover | 0.06 | 0.07 | 0.13 | 0.06 |
| Asset turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Average receivables | $1.4M | $445,000 | $175,000 | $142,000 |
| Average payables | $4.2M | $3.4M | $1.2M | $976,000 |
| Intangibles / total assets | 0.0% | 0.0% | 0.0% | 0.0% |
Computed from MBX's annual financial statements (latest annual report filed March 12, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
MBX valuation and financial ratios
MBX Biosciences earned a return on equity of −27.8% in fiscal 2025. It ended the year with $0.6 million of debt and $373.7 million in cash and short-term investments, a net cash position of $373.1 million.
See the MBX income statement, the MBX chart for price history, or the MBX stock overview for the latest quote and news.
MBX key metrics FAQ
What is MBX Biosciences's return on equity?
MBX Biosciences's return on equity (ROE) was −27.8% in fiscal 2025: net income of -$87.0 million on average shareholders' equity of $313.3 million.
How much debt does MBX Biosciences have?
MBX Biosciences had total debt of $0.6 million at the end of fiscal 2025, a debt-to-equity ratio of 0.00 and more cash than debt.
What is MBX Biosciences's free cash flow yield?
MBX Biosciences generated -$81.9 million of free cash flow in fiscal 2025, a free cash flow yield of −7.1% on its market value at year-end ($1.2 billion).
What is MBX Biosciences's current ratio?
MBX Biosciences's current ratio was 24.62 at the end of fiscal 2025: current assets were 24.62 times current liabilities.